Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2Active not recruiting 2Withdrawn 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Rectal Neoplasms 1Prostatic Neoplasms 1

Interventions

pembrolizumab 224Cyclophosphamide 192Radiotherapy 183Nivolumab 180Carboplatin 153Cisplatin 114Paclitaxel 112Dexamethasone 110Radiosurgery 104Magnetic Resonance Spectroscopy 97Surveys and Questionnaires 91Ipilimumab 81Doxorubicin 79Lenalidomide 76durvalumab 75Rituximab 75atezolizumab 72Radiation 72venetoclax 69fludarabine 68Standard of Care 68Gemcitabine 68Specimen Handling 65Etoposide 64Capecitabine 64Bevacizumab 62Oxaliplatin 59Docetaxel 58Biopsy 58Radiotherapy, Intensity-Modulated 56

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × OTHER × LY-2157299 × Clear all
NCT02688712 2026-04-13

ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer

Providence Health & Services

Phase 2 Active not recruiting
50 enrolled
Gastrointestinal

Rectal Neoplasms

NCT02452008 2025-12-19

Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Active not recruiting
60 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡